Recent Analysts’ Ratings Updates for Pfizer (PFE)

A number of firms have modified their ratings and price targets on shares of Pfizer (NYSE: PFE) recently:

• 9/13/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/10/2026 – Pfizer had its price target raised by HSBC Holdings plc from $28.00 to $30.00. They now have a “hold” rating on the stock.
• 9/5/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/31/2026 – Pfizer was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/17/2026 – Pfizer was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 8/7/2026 – Pfizer had its price target lowered by Guggenheim from $35.00 to $31.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Pfizer had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/1/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.